spacer
home > epc > summer 2018 > a blemish on good science
PUBLICATIONS
European Pharmaceutical Contractor

A Blemish on Good Science

In scientific research, objective data collection is critical to making conclusions that are free from bias. The importance of minimising subjectivity is particularly important in dermatology clinical trials where clinically acceptable methods of assessing disease symptoms or treatment response are largely based on a physician’s subjective assessment.

Dermatologists assess skin lesions and treatment responses using different observer-rated scales, such as the Eczema Area and Severity Index (EASI) and the Psoriasis Area and Severity Index (PASI). Both rely on visual assessments of symptoms, such as erythema (redness). This traditional approach of ‘eye-balling lesions’ results in subjective measurements prone to inter- and intra-observer variability (1). They can even vary at different times of the day.

Developing processes to objectively measure outcomes in dermatology clinical trials should be a priority for sponsors and investigators in this field. Thought leaders, including Dr James Milbauer, believe that, in the not-too-distant future, imaging technology and software will enable clinicians to scan, measure, and objectively assess patients and clinical trial participants (2). Until this technology becomes a reality, the pharmaceutical industry will continue to rely on alternative established strategies to mitigate the current lack of objectivity in measuring outcomes for dermatology trials. This article will discuss these strategies and the research that has created the first steps towards objective measurements for dermatology trials.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Elisabeth Rowold, Director of Project Management in the dermatology division (Europe), has more than 23 years of experience in the pharma industry and more than 14 years of experience in the conduct and oversight of clinical trials spanning all phases of cutaneous safety and efficacy studies. Elisabeth oversees the Novella Project Management activities in Europe and is responsible for providing strategic leadership, organisation, training, and ongoing evaluation and support to the Clinical Operations group.
spacer
Dr Elisabeth Rowold
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Fujifilm Announces The Introduction Of A 10 Week Cell Line Development Timeline With Its Apollo™ X Advanced Mammalian Expression System

FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies, has announced the reduction of cell line development timelines with its Apollo X™ Advanced Mammalian Expression System.
More info >>

White Papers

Inhaler Adherence: Exploring Key Factors

Aptar Pharma

Aptar Pharma recently hosted an expert panel roundtable on “Inhaler Adherence”. This international scientific forum was held in Paris, France on November 29th 2013. The roundtable was organized to explore and exchange views on the issues which may influence inhaler adherence/ compliance with a particular focus on asthma and C.O.P.D. therapies and their corresponding inhaler devices (MDIs, DPIs).
More info >>

 
Industry Events

Respiratory Drug Delivery (RDD®) Europe 2019

7-10 May 2019, Estoril Congress Center, Lisbon

Respiratory Drug Delivery (RDD®) Europe 2019 connects emerging and high-level scientists, academics, industrial and regulatory specialists, and clinicians. It is a must-attend conference for companies involved in research, development, testing or marketing of medicines, devices and services associated with pulmonary or nasal pharmaceutical products. This year, RDD Europe 2019 will be held in Estoril (Lisbon), Portugal, May 7-10, 2019, and, as in previous years is jointly organized by RDD Online and Aptar Pharma.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement